Anika Therapeutics, Inc. 10-Q filing
Filed 2026-07-29 · Report date 2026-06-30 · 2026
Filing metadata
- Accession number
- 0001171843-26-005012
- Form type
- 10-Q
- CIK
- 0000898437
- Primary document
- https://www.sec.gov/Archives/edgar/data/898437/000117184326005012/anik20260630_10q.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Anika Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $62.2M | - | - |
| Cost Of Revenue | $22.0M | - | - |
| Gross Profit | $40.2M | - | - |
| Operating Income | $-2.5M | - | - |
| Net Income | $-1.7M | - | - |
| Eps Basic | -0.13 | - | - |
| Eps Diluted | -0.13 | - | - |
| Cash And Equivalents | $38.4M | - | - |
| Total Assets | $183.5M | - | - |
| Shareholders Equity | $137.3M | - | - |
| Operating Cash Flow | $-5.5M | - | - |
| Capital Expenditures | $2.9M | - | - |